Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22963831 | 0.78 | FLT3 (0.41) | RPS6KB1MAPK1IRAK4CNR1FLT3 | |
| SCHEMBL13918462 | 0.74 | JAK2 (0.44) | AURKARPS6KB1MAPK1MAPK10IRAK4 | |
| SCHEMBL8941275 | 0.74 | JAK2 (0.44) | AURKARPS6KB1MAPK1MAPK10IRAK4 | |
| SCHEMBL8941007 | 0.74 | JAK2 (0.44) | AURKARPS6KB1MAPK1MAPK10IRAK4 | |
| SCHEMBL8994679 | 0.73 | NR4A2 (0.32) | IRAK4FLT3 | |
| SCHEMBL8989594 | 0.73 | ESR1 (0.36) | FLT3 | |
| SCHEMBL8990611 | 0.69 | NTRK1 (0.40) | — | |
| SCHEMBL3838995 | 0.66 | CDK2 (0.42) | AURKARPS6KB1MAPK1MAPK10P2RX7 | |
| SCHEMBL13918619 | 0.65 | CCNT1 (0.42) | IRAK4SLC6A4 | |
| SCHEMBL4797985 | 0.64 | FADS1 (0.55) | AURKARPS6KB1MAPK1MAPK10SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | AURKA 161/4885RPS6KB1 643/4885MAPK1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.